Clinical Significance of Measuring Serum p53 Antibodies in Colorectal Cancer Patients

DOI Web Site 2 Citations 33 References
  • Ota Mitsuyoshi
    Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine
  • Fujii Shoichi
    Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine
  • Ichikawa Yasushi
    Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine
  • Suwa Hirokazu
    Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine
  • Tatsumi Kenji
    Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine
  • Watanabe Kazuteru
    Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine
  • Yamagishi Shigeru
    Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine
  • Tanaka Kuniya
    Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine
  • Akiyama Hirotoshi
    Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine
  • Endo Itaru
    Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine

Bibliographic Information

Other Title
  • 大腸癌における血清ｐ５３抗体測定の意義

Search this article

Description

To evaluate the clinical significance of the serum p53 antibody in colorectal cancers, we preoperatively measured tumor markers, including the serum p53 antibody in 251 cases of colorectal cancer and compared them to patient profiles. Tumor markers were 31.2% positive for CEA, 15.8% positive for CA 19-9, and 31.6% positive for p53. The percentage of more than one of these markers being positive was 60.0%. In patients with fecal occult blood, p53 antibodies were significantly more positive than CEA (p=0.0215). In stage I subjects, p53 antibodies were significantly higher than CEA (p=0.0003). In 28 cases of synchronous multiple cancer, p53 antibodies were positive in 53.6% significantly higher than in those with single cancer. In 8 cases of synchronous double cancer, positive p53 antibodies were 50%. These results indicate the need to carefully check for synchronous multiple and double cancer in subjects in whom p53 antibodies are positive.

Journal

Citations (2)*help

See more

References(33)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top